Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Research Rheum

Data Accumulate to Suggest HLA-B27 Status May Drive Axial Phenotype in SpA

Lara C. Pullen, PhD  |  May 20, 2022

HLA-B27 may be a phenotypic expression of axial spondyloarthritis (SpA), according to a large international study. The study found patients with axial SpA who were positive for HLA-B27 had more severe radiographic damage than those who were negative for HLA-B27, and three quarters of study patients with ankylosis spondyloarthritis were HLA-B27 positive.

Diagnosing & Caring for Patients with Fibromyalgia

Lara C. Pullen, PhD  |  May 19, 2022

Doebl et al. compared the effect of symptoms and the healthcare use of people with fibromyalgia with those who fulfilled the criteria for fibromyalgia but had not been diagnosed and those with chronic pain. They found patients diagnosed with fibromyalgia reported the poorest healthcare experiences and were more likely than other study participants to be unemployed due to health issues. Their findings reveal an urgent need exists for a model of care for patients with fibromyalgia.

Scleroderma & the Gut: New Frontiers in Diagnosis & Tips on Management

Samantha C. Shapiro, MD  |  May 12, 2022

McMahan et al. examined how abnormal gastrointestinal (GI) transit may contribute to GI severity and symptoms in patients with systemic sclerosis (SSc). About 90% of people with SSc have GI tract involvement, and understanding the connection between GI symptoms, their severity and abnormal GI transit may permit targeted therapeutic approaches for these patients.

Study: Don’t Automatically Blame Burnout on Electronic Health Records

Leslie Mertz, PhD  |  May 12, 2022

When it comes to experiencing burnout, time spent in an electronic health records (EHR) system appears to be only a minor contributing factor. Although clinicians and other healthcare professionals may log many hours at the keyboard putting information into the EHR, other factors likely play a bigger role in the workplace exhaustion and feelings of…

Lightspring / shutterstock.com

Study Finds Potential Biomarkers for Cardiovascular Risk in Women with Lupus

Elizabeth Hofheinz, MPH, MEd  |  May 12, 2022

When it comes to systemic lupus erythematosus (SLE) and cardio­vascular events (CVEs), the rheumatology community is woefully lacking in information, say researchers from the University of California, Los Angeles (UCLA) David Geffen School of Medicine and Cedars-Sinai Medical Center. Their recent work on biomarkers associated with an increased risk for cardiovascular events in women with…

Recent Research: Study Summaries from Arthritis Care & Research

Meghan Angley, PhD, & S. Sam Lim, MD, Tiffany Dharia, MD, & Michael George, MD, Emily F. Neves Yuki, PhD, & Eloisa Bonfa, PhD  |  May 12, 2022

Lupus & Perinatal Outcomes Adverse perinatal outcomes before & after diagnosis with systemic lupus erythematosus among African American Women By Meghan Angley, PhD, & S. Sam Lim, MD Why was this study done? Previous studies have suggested that women with systemic lupus erythematosus (SLE) may experience adverse perinatal outcomes, including preterm and small-for-gestational-age birth, in…

Remission Definitions in RA: Common Questions & Implications for Clinical Practice

Samantha C. Shapiro, MD  |  May 5, 2022

A recent editorial provides new insights by reexamining the definitions of remission for rheumatoid arthritis and outlining concerns with the use of specific metrics for remission in clinical trials.

Outcomes in Patients with Rheumatic Diseases & COVID-19

Arthritis & Rheumatology  |  April 26, 2022

Background & objectives: Patients with rheumatic and musculoskeletal diseases (RMDs) may be at an increased risk of SARS-CO-V2 infection as a result of underlying disease, associated comorbidities and use of potentially immunosuppressive treatments. Further, concern exists regarding whether individuals with rheumatic diseases potentially experience more severe COVID-19 and poorer outcomes. This study was undertaken to…

Study: COVID-19 Vaccinations Are Safe for Patients with Lupus

Thomas R. Collins  |  April 15, 2022

COVID-19 vaccinations are safe for patients with systemic lupus erythematosus (SLE), with manageable side effects and a low incidence of flare, according to a recently published study in The Lancet.1 The use of mRNA vaccines, such as those from Pfizer-BioNTech and Moderna, which have been viewed as riskier than traditional vaccines because of a concern…

Is Hydroxychloroquine Safe During Pregnancy?

Arthritis & Rheumatology  |  March 31, 2022

Chambers et al. found no evidence of an increased risk of major structural birth defects nor any increase in a wide range of other pregnancy outcomes attributable to prenatal exposure to hydroxychloroquine.

  • « Previous Page
  • 1
  • …
  • 8
  • 9
  • 10
  • 11
  • 12
  • …
  • 126
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences